Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)

Phase 3

Completed

• Conditions: Extreme Prematurity
• Interventions: Other: Control; Drug: Epo

• Registration Number: NCT01378273
• Lead Sponsor: University of Washington

Brief Summary

Recombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects oligodendrocytes from injury.

We hypothesize that neonatal Epo treatment of ELGANs will decrease the combined outcome of death or severe NDI from 40% to 30% (primary outcome), or the combined outcome of death plus moderate or severe NDI from 60% to 40% (secondary outcome) measured at 24-26 months corrected age.

1. To determine whether Epo decreases the combined outcome of death or NDI at 24-26 months corrected age. NDI is defined as the presence of any one of the following: CP, Bayley Scales of Infant and Toddler Development, 3rd Edition (Bayley-III) Cognitive Scale \< 70 (severe, 2 SD below mean) or 85 (moderate, 1 SD below mean). CP will be diagnosed and classified by standardized neurologic exam, with severity classified by Gross Motor Function Classification System (GMFCS).

2. To determine whether there are risks to Epo administration in ELGANs by examining, in a blinded manner, Epo-related safety measures comparing infants receiving Epo with those given placebo.

3. To test whether Epo treatment decreases serial measures of circulating inflammatory mediators, and biomarkers of brain injury.

4. To compare brain structure (as measured by MRI) in Epo treatment and control groups at 36 weeks PMA. MRI assessments will include documentation of intraventricular hemorrhage (IVH), white matter injury (WMI) and hydrocephalus (HC), volume of total and deep gray matter, white matter and cerebellum, brain gyrification, and tract-based spatial statistics (TBSS based on diffusion tensor imaging). As an exploratory aim, we will determine which of the above MRI measurements best predict neurodevelopment (CP, cognitive and motor scales) at 24-26 months corrected age.

Anticipated outcomes: Early Epo treatment of ELGANs will decrease biochemical and MRI markers of brain injury, will be safe, and will confer improved neurodevelopmental outcome at 24-26 months corrected age compared to placebo, and will provide a much-needed therapy for this group of vulnerable infants.

Detailed Description

This is a randomized, placebo-controlled, study of Epo treatment of preterm infants 24-0/7 to 27-6/7 weeks of gestation, beginning in the first 24 hours after birth. Randomization will be stratified by site and gestational age at birth (\<26 week or 26-27-6/7). Study size sample is 940 patients. We expect to evaluate 752 subjects at 24-26 months corrected age, our primary endpoint. There is no enrollment restriction based on gender, ethnicity or race. Enrollment is expected to take 24-26 months, with each subject participating through 24-26 months corrected age when neurodevelopmental outcomes are assessed. The combined outcome of death or severe NDI will be compared between Epo-treated and control subjects. All outcomes will be collected in a blinded manner. Subjects will be randomized by the data-coordinating center (DCC) to Epo treatment or placebo, and Epo treatment will continue until 32-6/7 weeks post menstrual age. Serial measurements of circulating inflammatory mediators and biomarkers of brain injury will be made. A brain MRI will be done at 36 weeks post menstrual age in the same subset of infants. Phone contact will occur at 4, 8, 12, and 18 months. Face to face follow up will occur at 24-26 months corrected age. The primary outcome is death or severe NDI at 24-26 months corrected age, with a secondary outcome of death or moderate NDI. Our primary sample size calculation is based on the conservative assumptions that Epo treatment will result in a 40% reduction in the severe NDI rate (the range in animal studies is 49-70%) and minimal impact on death. This would yield a control group rate for the primary outcome of 40.4% and an expected treated rate of 31.5% thus yielding an 8.9% lower rate of Death + NDI.

Clinical information including co-morbidities of extreme prematurity, information about transfusions, and specific laboratory values were collected in the PENUT database.

Study Timeline

• Study First Submitted: 2011-06-20
• Study First Submitted QC: 2011-06-21
• Study First Posted: 2011-06-22
• Study Start: 2013-12
• Primary Completion: 2019-02-28
• Study Completion: 2020-02-28
• Results First Submitted: 2020-07-02
• Status Verified: 2020-08
• Results First Submitted QC: 2020-08-06
• Last Update Submitted: 2020-08-14
• Results First Posted: 2020-08-17
• Last Update Posted: 2020-08-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 941

Inclusion Criteria

1. NICU inpatients between 24-0/7 and 27-6/7 weeks of gestation
2. Less than twenty four hours of age
3. Parental informed consent

Read More

Exclusion Criteria

1. Major life-threatening anomalies (brain, cardiac, chromosomal anomalies)
2. Hematologic crises such as DIC, or hemolysis due to blood group incompatibilities
3. Polycythemia (hematocrit > 65)
4. Congenital infection

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control	Control	Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
Epo 1000 U/kg followed by 400 U/kg	Epo	Subjects will receive 6 doses of intravenous Epo 1000 U/kg/dose at 48 hour intervals from the time of enrollment. Following the high dose period, subjects will receive subcutaneous Epo 400 U/kg/dose three times a week until 32-6/7 weeks postmenstrual age.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Death or Severe Neurodevelopmental Impairment (NDI) at 22-26 Months Corrected Age	22-26 months corrected age	Severe NDI was defined as Bayley Scales of infant Development, 3rd edition composite motor score or composite cognitive score \<70. This instrument is normed at 100 with standard deviation of 15.; Cerebral palsy was classified as hemiplegia, diplegia, or quadriplegia, and severity was determined according to the Gross Motor Function Classification System (GMFCS) (levels range from 0 \[no impairment\] to 5 \[most severe impairment\]). Severe cerebral palsy was defined as a GMFCS level higher than 2.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With a Serious Adverse Events (SAE)	From birth to hospital discharge (average 12-16 weeks depending on gestational age at birth)	Serious adverse events were prespecified. These included any symptomatic thrombosis involving a major vessel, unrelated to an infusion catheter requiring anticoagulation therapy, hematocrit level \>65% or an increase of ≥15% in hematocrit in the absence of a preceding blood transfusion, hypertension (defined by receipt of antihypertensive therapy for more than 1 month, discharge with medication, or both), severe pulmonary hemorrhage, severe necrotizing enterocolitis (defined as Bell's stage 2b or 3), severe retinopathy of prematurity resulting in laser surgery or bevacizumab therapy, severe sepsis (defined as culture-proven bacterial or fungal sepsis resulting in blood-pressure support or substantive new respiratory support), grade 3 or 4 intracranial hemorrhage, cardiac arrest that did not result in death, and death.
Imaging	36 weeks postmenstrual age	Brain MRI at 36 weeks PMA. Injury scoring was done using a modified scoring system of Kidokoro, with higher scores indicating greater brain injury. Scoring Range: 0-39
Biomarkers	Baseline (first 24 hours after birth), days 7, 9 and 14 after birth	Plasma Epo concentrations were measured in both groups within the first 24 h after birth before study drug administration (baseline), 30 minutes after study drug administration on day 7 (peak Epo concentration) and 30 minutes before study drug on day 9 (trough Epo) and a random level on day 14 after transition to subcutaneous dosing.

Trial Locations

Locations (19)

Wake Forest School of Medicine; 🇺🇸 Winston-Salem, North Carolina, United States

Florida Hospital; 🇺🇸 Orlando, Florida, United States

University of New Mexico Children's Hospital; 🇺🇸 Albuquerque, New Mexico, United States

University of Louisville; 🇺🇸 Louisville, Kentucky, United States

Johns Hopkins; 🇺🇸 Baltimore, Maryland, United States

Children's Hospital of Minnesota, St. Paul; 🇺🇸 Saint Paul, Minnesota, United States

Prentice Women's Hospital; 🇺🇸 Chicago, Illinois, United States

Children's Hospital of the University of Illinois; 🇺🇸 Chicago, Illinois, United States

All Childrens Hospital; 🇺🇸 Saint Petersburg, Florida, United States

Beth Israel Deaconess Hospital; 🇺🇸 Boston, Massachusetts, United States

Maia Fareri Children's Hospital; 🇺🇸 Valhalla, New York, United States

University of Washington; 🇺🇸 Seattle, Washington, United States

South Miami Hospital; 🇺🇸 Miami, Florida, United States

Children's Hospital of Minnesota, MN; 🇺🇸 Minneapolis, Minnesota, United States

University of Minnesota Amplatz Children's Hospital; 🇺🇸 Minneapolis, Minnesota, United States

Methodist Children's Hospital; 🇺🇸 San Antonio, Texas, United States

University of Utah; 🇺🇸 Salt Lake City, Utah, United States

University of Florida; 🇺🇸 Gainesville, Florida, United States

University of Arkansas; 🇺🇸 Little Rock, Arkansas, United States